Quick Answer
CARLSMED, INC. reported Cash and Equivalents of $85.79 million for fiscal year 2025.
CARLSMED, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $85.79M | +113.8% |
| 2024 | $40.12M | +455.6% |
| 2023 | $7.22M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $115.37M | +159.6% | +244.7% |
| June 30, 2025 | $33.47M | -12.3% | -16.6% |
| December 31, 2024 | $40.12M | +455.6% | -9.7% |
| September 30, 2024 | $44.44M | — | +16.5% |
| June 30, 2024 | $38.15M | — | +428.2% |
| December 31, 2023 | $7.22M | — | — |
- CARLSMED, INC. showed an increase of +113.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, CARLSMED, INC.’s cash and equivalents has grown by 1087.9% (from $7.22 million to $85.79 million).
- The most recent figure is from CARLSMED, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: